Skip to main content

Table 1 Baseline characteristics of patients treated with free combination therapy compared with those treated with dutasteride 0.5 mg or tamsulosin 0.4 mg monotherapy, after adjustment using inverse probability of treatment weight

From: Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database

 

Free combination therapy versus dutasteride monotherapy

Free combination therapy versus tamsulosin monotherapy

Free combination of dutasteride plus tamsulosin therapy (n = 1527)

Dutasteride monotherapy (n = 6661)

Std. diff* (%)

Free combination of dutasteride plus tamsulosin therapy (n = 1544)

Tamsulosin monotherapy (n = 6574)

Std. diff* (%)

Age, n (%)

 40–49 years

29 (1.9)

150 (2.2)

2.3

20 (1.3)

90 (1.4)

0.7

 50–59 years

165 (10.8)

704 (10.6)

0.8

182 (11.8)

777 (11.8)

0.2

 60–69 years

488 (32.0)

2133 (32.0)

0.1

517 (33.5)

2201 (33.5)

0.0

 ≥ 70 years

844 (55.3)

3675 (55.2)

0.3

826 (53.5)

3506 (53.3)

0.3

Clinical characteristics, n (%)

 Any AE

422 (27.7)

1857 (27.9)

0.5

476 (30.8)

2030 (30.9)

0.1

 Cardiovascular disease

565 (37.0)

2475 (37.2)

0.3

622 (40.3)

2612 (39.7)

1.2

 Hyperlipidemia

304 (19.9)

1361 (20.4)

1.3

338 (21.9)

1433 (21.8)

0.3

 Chronic pulmonary disease

221 (14.5)

988 (14.8)

0.9

258 (16.7)

1088 (16.5)

0.4

 BPH with LUTS

210 (13.7)

889 (13.3)

1.1

288 (18.6)

1193 (18.2)

1.2

 Polyuria§

167 (10.9)

709 (10.6)

1.0

225 (14.6)

936 (14.2)

1.0

Concomitant medications, n (%)

 NSAIDs

530 (34.7)

2302 (34.6)

0.4

585 (37.9)

2417 (36.8)

2.3

 Calcium channel blockers

330 (21.6)

1400 (21.0)

1.4

374 (24.2)

1500 (22.8)

3.3

 Antihypertensives

334 (21.9)

1454 (21.8)

0.1

361 (23.4)

1459 (22.2)

2.8

  1. AE, adverse event; BPH, benign prostatic hyperplasia; LUTS, lower urinary tract symptoms; NSAIDs, nonsteroidal anti-inflammatory drugs;
  2. Std. diff, standardized difference
  3. *For continuous variables, the standardized difference was calculated by dividing the absolute difference in means of the free combination therapy cohort and reference monotherapy cohorts by the pooled standard deviation (SD) of both groups, for each comparison. The pooled SD was the square root of the average of the squared SD. For dichotomous variables, the standardized difference was calculated using the following equation where P is the respective proportion of participants in each treatment cohort: [(Pfreecombination therapy- Preference)/ √(Pfreecombinationtherapyx(1 – Pfreecombinationtherapy) + Preference x (1 – Preference))/ 2]
  4. For the purpose of this analysis, the data on prostate cancer were included in any AE. See Additional file 2 for list of AEs
  5. Three categories of Quan–Charlson comorbidities (ie, congestive heart failure, peripheral vascular disease, and myocardial infarction) are listed under cardiovascular disease
  6. §Polyuria includes nocturia and urinary frequency